Astellas Pharma Inc - Company Profile

Powered by

All the data and insights you need on Astellas Pharma Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Astellas Pharma Inc Strategy Report

  • Understand Astellas Pharma Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.

Gain a 360-degree view of Astellas Pharma Inc and make more informed decisions for your business Gain a 360-degree view of Astellas Pharma Inc and make more informed decisions for your business Find out more
Headquarters Japan

Address 2-5-1, Nihombashihon-Cho, Chuo-Ku, Tokyo, 103-8411


Telephone 81 3 32443000

No of Employees 14,484

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 4503 (TYO)

Revenue (2023) $11.2B 17.2% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ -20.4% (2023 vs 2022)

Market Cap* $20.2B

Net Profit Margin (2023) XYZ -32.1% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Astellas Pharma Inc premium industry data and analytics

1,500+

Clinical Trials

Determine Astellas Pharma Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

470+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Astellas Pharma Inc’s relevant decision makers and contact details.

390+

Catalyst Calendar

Proactively evaluate Astellas Pharma Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

360+

Pipeline Drugs

Identify which of Astellas Pharma Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

150+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

110+

Marketed Drugs

Understand Astellas Pharma Inc’s commercialized product portfolio to stay one step ahead of the market.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Astellas Pharma Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

40+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Astellas Pharma Inc (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Astellas Pharma Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Xtandi- Treatment of Prostate Cancer
Xospata- Acute Myeloid Leukemia
Padcev- Metastatic Urothelial Cancer
XYZ
XYZ
XYZ
Understand Astellas Pharma Inc portfolio and identify potential areas for collaboration Understand Astellas Pharma Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 New Products/Services In February, the company launched a new monotherapy to treat patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation (FLT3mut+)1.
2024 Regulatory Approval In February, the company received approval from Japan's Ministry of Health, Labour and Welfare for the company's supplemental new drug application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with metastatic urothelial cancer.
2024 Contracts/Agreements In January, the company and Mass General Brigham announced a collaboration to improve translational medicine and accelerate the early development of novel therapies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Astellas Pharma Inc Daiichi Sankyo Co Ltd Eisai Co Ltd Kyowa Kirin Co Ltd Taisho Pharmaceutical Holdings Co Ltd
Headquarters Japan Japan Japan Japan Japan
City Chuo-Ku Chuo-Ku Bunkyo-Ku Chiyoda-Ku Toshima-Ku
State/Province Tokyo Tokyo Tokyo Tokyo Tokyo
No. of Employees 14,484 17,435 11,076 5,982 8,784
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Kenji Yasukawa Chairman Executive Board 2023 -
Naoki Okamura Chief Executive Officer; Director; President Executive Board 2023 -
Atsushi Kitamura Chief Financial Officer Senior Management 2023 -
Adam Pearson Chief Strategy Officer Senior Management 2023 -
Katsuyoshi Sugita Chief Ethics and Compliance Officer; Chief People Officer; Executive Vice President Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Astellas Pharma Inc key executives to enhance your sales strategy Gain insight into Astellas Pharma Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward